title: Type 2 diabetes: treat to target.
abstract: Traditionally, practitioners have reserved insulin therapy for patients with type 2 diabetes until diet, exercise, and treatment with oral agents have failed to maintain glycemic control. Increasing evidence, however, supports advancing insulin therapy earlier in treating diabetes, not only to normalize glycemic control and emulate normal physiologic insulin secretion, but also to delay or prevent disease-associated comorbidity.
authors.affiliation: Michigan Diabetes Research and Training Center, Ann Arbor, Mich, USA.
authors.forename: Martha M
authors.initials: MM
authors.lastname: Funnell
authors.forename: Davida F
authors.initials: DF
authors.lastname: Kruger
mesh_terms: D001786:Blood Glucose / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D018450:Disease Progression; D004334:Drug Administration Schedule; D016903:Drug Monitoring / Q000379:methods*; D004359:Drug Therapy, Combination; D006801:Humans; D007328:Insulin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D013453:Sulfonylurea Compounds / Q000627:therapeutic use
chemical_list: D001786:Blood Glucose; D007328:Insulin; D013453:Sulfonylurea Compounds